Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2023-11-14 00:00:00 ET · period of report 2023-11-09 · accession 0001610717-23-000356 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-11-14 | 2023-11-09 | RVMD | Horning Sandra | Dir | A - Grant | $0.00 | +90.5K | 80.0K | New | $0 |
| DM | 2023-11-14 | 2023-11-09 | RVMD | Horning Sandra | Dir | A - Grant | $0.00 | +47.5K | 36.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-09 | A | A | 52,291 | — | 52,291 | D | — | — | (F1) Pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (the "Merger Agreement"), at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. |
| 2 | Common | Common Stock | 2023-11-09 | A | A | 10,500 | $0.00 | 90,487 | D | — | — | (F3) Includes 10,500 restricted stock units. |
| 3 | Common | Common Stock | 2023-11-09 | A | A | 27,696 | — | 79,987 | D | — | — | (F2) Pursuant to the Merger Agreement, at the Effective Time, a stock option to purchase shares of EQRx, Inc. common stock that was outstanding immediately prior to the Effective Time was cancelled and converted automatically into the right to receive 27,696 shares of the Company's common stock. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. |
| 4 | Derivative | Earn-out Shares | 2023-11-09 | A | A | 10,651 | — | 10,651 | D | — · — to 2024-12-17 | 10,651 Common Stock | (F4) Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 95,784 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 10,651 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving her interests in the Earn-out Shares. |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-11-09 | A | A | 36,800 | $0.00 | 36,800 | D | $20.02 · — to 2033-11-08 | 36,800 Common Stock | (F5) The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/36 of the shares subject thereto on each monthly anniversary of November 8, 2023, subject to the reporting person's continued employment or service relationship with the Company on each such vesting date. |